Related Experiment Video
Updated: Jul 3, 2026
09:11
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model
Mark H Criswell1, Wen-Zheng Hu, Timothy J Steffens
1Retina Service Research Laboratories, Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Cir, Indianapolis, IN 46202-5175, USA. mcriswel@iupui.edu
Archives of Ophthalmology (Chicago, Ill. : 1960)
|July 16, 2008
Summary
Intravitreal pegaptanib showed minimal effect on choroidal neovascularization (CNVM) development in an animal model. In contrast, triamcinolone acetonide effectively inhibited CNVM formation, suggesting pegaptanib may be insufficient for preventing CNVM.
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Background:
- Choroidal neovascularization (CNVM) is a key pathological feature in various retinal diseases.
- Developing effective prophylactic treatments for CNVM is crucial for preserving vision.
Purpose of the Study:
- To assess the prophylactic efficacy of intravitreal pegaptanib sodium against laser-induced CNVM.
- To compare the anti-CNVM performance of pegaptanib with triamcinolone acetonide.
Main Methods:
- CNVMs were induced in an animal model using laser trauma.
- Animals received intravitreal injections of pegaptanib (8 or 17 µg), triamcinolone acetonide (200 µg), or vehicle.
- CNVM size and thickness were evaluated histologically, and leakage was assessed via fluorescein angiography after 21 days.
Main Results:
- Pegaptanib treatment resulted in 10-13% smaller CNVM diameters compared to controls.
- Triamcinolone acetonide significantly reduced CNVM diameters by 43% and thickness to 26 µm.
- Fluorescein angiography showed less leakage in triamcinolone-treated eyes (0.6) versus pegaptanib-treated (1.5) and control eyes (2.0).
Conclusions:
- Intravitreal pegaptanib demonstrated limited efficacy in preventing CNVM development in this model.
- Intravitreal triamcinolone acetonide exhibited potent inhibition of CNVMs.
- Pegaptanib may not be a sufficient therapeutic option for CNVM prevention.
